Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality

BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) is a life-threatening disease with increasing prevalence in patients with rheumatic disease. Trimethoprim/sulfamethoxazole (TMP/SMX) is an effective treatment for patients with rheumatic disease hospitalized for PJP. This study aimed to describe the...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Siyang, Zhang, Yang, Yu, Jie, Xie, Cuiying, Chen, Yi, Zhang, Xingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793549/
https://www.ncbi.nlm.nih.gov/pubmed/36575406
http://dx.doi.org/10.1186/s12879-022-07940-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793549/
https://www.ncbi.nlm.nih.gov/pubmed/36575406
http://dx.doi.org/10.1186/s12879-022-07940-z

Ejemplares similares